Achieve Life Sciences (NASDAQ:ACHV - Get Free Report) released its quarterly earnings results on Tuesday. The biopharmaceutical company reported ($0.36) earnings per share for the quarter, missing the consensus estimate of ($0.30) by ($0.06), Zacks reports.
Achieve Life Sciences Trading Down 2.5 %
Achieve Life Sciences stock opened at $3.06 on Tuesday. The company has a market cap of $105.23 million, a price-to-earnings ratio of -2.71 and a beta of 1.67. The firm has a 50-day moving average of $3.23 and a 200-day moving average of $4.06. The company has a debt-to-equity ratio of 0.31, a current ratio of 6.78 and a quick ratio of 6.78. Achieve Life Sciences has a one year low of $2.82 and a one year high of $5.59.
Analyst Ratings Changes
A number of equities analysts recently weighed in on ACHV shares. RODMAN&RENSHAW raised shares of Achieve Life Sciences to a "strong-buy" rating in a research note on Thursday, November 14th. Rodman & Renshaw initiated coverage on Achieve Life Sciences in a research report on Thursday, November 14th. They set a "buy" rating and a $12.00 price objective for the company. Three research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company. Based on data from MarketBeat, Achieve Life Sciences has a consensus rating of "Buy" and an average target price of $15.75.
View Our Latest Report on Achieve Life Sciences
About Achieve Life Sciences
(
Get Free Report)
Achieve Life Sciences, Inc, a clinical-stage pharmaceutical company, develops and commercializes cytisinicline for smoking cessation and nicotine addiction. The company offers cytisinicline, a plant-based alkaloid that interacts with nicotine receptors in the brain that reduce the severity of nicotine withdrawal symptoms.
Read More
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Achieve Life Sciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Achieve Life Sciences wasn't on the list.
While Achieve Life Sciences currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
